Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

CareDx: Art Torres

CareDx has appointed patient advocate, political leader, and former state senator Art Torres to its board of directors.

Torres began his career by working alongside Cesar Chavez for the rights of farm workers in California. He later served for 20 years in the California legislature, chairing the State Assembly’s Health Committee, and then was elected as chair of the State Democratic Party. He is also a colon cancer survivor.

Currently, Torres serves as vice chair of the governing board of the California Institute for Regenerative Medicine, as well as a member of the University of California Board of Regents and the Covered California board overseeing the Affordable Care Act. He is also the vice chair on the board of One Legacy, an organ transplant foundation based in Southern California.

Owlstone Medical: Mark Capone

Owlstone Medical has appointed Mark Capone to its board as an independent non-executive director. Capone recently served as president and CEO of Myriad Genetics, and prior to Myriad, he spent 17-years at Eli Lilly in various positions. He is president and CEO of Precision Medicine Advisors and a non-executive board member of Abcam, Micoba Life Sciences, and NephroSant. Following Capone's appointment, the Owlstone Medical board comprises seven members including one executive director and two independent non-executive directors.

Sera Prognostics: Michael Foley

Sera Prognostics has appointed Michael Foley its CMO, starting in January 2022. He is currently chairman of obstetrics and gynecology at the University of Arizona College of Medicine Phoenix/Banner good Samaritan Regional Medical Center, from which he will retire on Dec. 31, 2021. He is also the lead editor of Obstetric Intensive Care: A Practical Manual.

Tesis Labs: Jonathan Stein

Jonathan Stein has been named as the first CSO and medical director of Tesis Labs, a genetic testing company based in Phoenix, Arizona. Previously, he was CSO at Spectracell Laboratories after serving as the company's lab director. Before that, he was medical director and clinical consultant at Apex Molecular Laboratories, associated DNA lab director at Identigene, and a research investigator at the University of Texas MD Anderson Cancer Center. Stein holds a PhD in molecular and cancer genetics and a master's degree in population and biomedical sciences from the University of Texas Health Science Center as well as a bachelor's degree in biochemistry from the University of California, Santa Cruz.

Dante Labs: Andre Nel, Dalila Rahmani, Laura D'Angelo, Omar Elbakshish, Rachel Haverfield

Dante Labs has appointed Andre Nel as CFO, Dalila Rahmani as chief accounting officer, Laura D'Angelo as VP of investor relations, Omar Elbakshish as senior director of business finance, and Rachel Haverfield as general counsel.

Nel, Rahmani, Elbakshish, and Haverfield come to Dante from Illumina. Nel was VP of finance at Illumina and previously worked at Pfizer. Rahmani most recently led the commercial finance team at Illumina. Before, she was an auditor at Ernst & Young. Haverfield was previously VP of legal EMEA at Illumina.

D'Angelo joins Dante from Invitae, where she was head of investor relations.

Lumos Diagnostics: Jerome Adams

Former US Surgeon General Jerome Adams has joined Lumos Diagnostics as a strategic healthcare adviser. He also will be appointed to the Sarasota, Florida-based firm's medical advisory board. Adams was the surgeon general during the Trump administration. At Lumos, he will advise Lumos on the deployment of its point-of-care diagnostic technologies, including the launch of the FebriDx test, which can differentiate whether a person has a bacterial or viral infection within 10 minutes. The test is available in Europe, the UK, Canada, and Australia and is under regulatory review in the US, the firm said. Adams is currently an assistant professor of clinical anesthesia at Indiana University and a staff anesthesiologist at Eskanazi Health.

 

SQI Diagnostics: Andrew Morris

SQI Diagnostics has appointed Andrew Morris as CEO, effective Sept. 11. Morris is currently a director of the firm and most recently served as managing partner of medical device manufacturer Attwill Medical Solutions. He was previously CEO and CFO of SQI and took the company public in 2007. Morris is also the president of Rare Management Advisors.

Clive Beddoe has stepped down as interim CEO and will continue to serve as executive chair and a director of the company. 

Sysmex: Ralph Taylor, Andy Hay

Ralph Taylor, CEO of diagnostics company Sysmex America, will retire effective September 30. He will be replaced by Andy Hay, currently the company's chief operating officer. 

Hay has been with Sysmex for 32 years and took over as chief operating officer in 2018. During his time with Sysmex, Hay has led key commercial operations areas including sales, marketing, R&D, training, and operations for Sysmex America. 

Cue Health: David Arida

Diagnostic testing firm Cue Health has appointed David Arida as chief operating officer. Arida joins Cue from Dexcom, a diabetes care technology company, where he served in multiple senior operational roles since 2011, most recently as senior vice president of global manufacturing operations. Prior to Dexcom, Arida held a number of management, consulting, or engineering positions at Alere (now Abbott), Amylin Pharmaceuticals (now AstraZeneca), and PRTM (now PWC). 

YourBio Health: Stephen Hahn

YourBio Health has appointed Stephen Hahn as its interim chief medical officer. Hahn served as the US Food and Drug Administration commissioner from 2019 to 2021. Prior to joining the FDA, Hahn was the chief medical executive at MD Anderson Cancer Center in Houston, and prior to MD Anderson, he was head of the radiation oncology department at the University of Pennsylvania’s Perelman School of Medicine.

During his time as an active clinician, Hahn specialized in treating thoracic, sarcoma, and genitourinary cancers, as well as the use of photodynamic therapy for the treatment of pre-invasive and invasive malignancies.